|Awarded On||August 21, 2019|
|Title||Novel High-Throughput Microfluidic Device for Isolating T-cells Directly from Whole Blood to Simplify Manufacturing of Cellular Therapies|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||University of Houston|
|Principal Investigator/Program Director||Sergey S Shevkoplyas|
|Cancer Sites||All Sites|
*Pending contract negotiation
The use of novel chimeric antigen receptor (CAR)-modified T-cells as a highly effective treatment for various types of cancer continues to expand. To receive a CAR T-cell treatment, cancer patients must first undergo leukapheresis, a highly specialized, expensive procedure during which 10-15 liters of patient’s blood are continuously recirculated, over several hours, through an apheresis machine to extract a sample enriched with patient’s T-cells. Because the leukapheresis sample also contains large quantities of unwanted cells that may interfere with the subsequent CAR T-cell manufacturing process, the sample is further processed via density gradient centrifugation to remove the unwanted ...